MedTrace Logo

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

NCT07595172 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-05-19

No results posted yet for this study

Summary

This study aims to evaluate the safety and preliminary efficacy of NALIRIFOX combined with adebrelimab and PULSAR as first-line treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). Additionally, it will explore potential predictive and efficacy-related biomarkers.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Locally Advanced and Metastatic Pancreatic Cancer

Interventions

DRUG

NALIRIFOX+Adebrelimab

NALIRIFOX chemotherapy and Adebrelimab Injection

RADIATION

PULSAR

PULSAR

Sponsors & Collaborators

  • Jiangsu Hengrui Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • West China Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2028-08-31
Completion
2029-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07595172 on ClinicalTrials.gov